Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

RUNX1-RUNX1 homodimerization modulates RUNX1 activity and function.

Donglan Li1, Kislay K Sinha, Maher A Hay

  • 1Department of Medicine, University of Illinois, Chicago, Illinois 60612, USA.

The Journal of Biological Chemistry
|March 16, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of <i>TP53</i>-mutated myelodysplastic syndrome and acute myeloid leukemia with lowintensity metronomic decitabine and venetoclax.

Haematologica·2026
Same author

Pyrimethamine overcomes resistance to hypomethylating agents by reducing de novo pyrimidine synthesis.

Experimental hematology·2026
Same author

Combining drugs that bypass p53 to treat TP53-mutated leukemias.

Blood advances·2025
Same author

Alterations in calreticulin and CD47 expression dynamics in myeloid malignancies: therapeutic and prognostic implications in myelodysplastic syndromes and myeloproliferative neoplasms.

Haematologica·2025
Same author

Metronomic low-dose regimen of decitabine and venetoclax is safe and reduces monocyte burden in chronic myelomonocytic leukemia.

Haematologica·2025
Same author

Epigenetic drug remedies for SCD root cause pathophysiology.

Blood·2025
Same journal

Correction: Characterization of Mast2 kinase defines structural features, regulation, and substrates.

The Journal of biological chemistry·2026
Same journal

Isotope-Edited ESEEM: A New Method for Probing Copper Binding Sites in Neurodegenerative Proteins.

The Journal of biological chemistry·2026
Same journal

Introduction to the Thematic Review Series on Intracellular Protein Degradation. The ubiquitous biology of intracellular protein degradation: a tribute to Alfred L. ("Fred") Goldberg.

The Journal of biological chemistry·2026
Same journal

Correction: Aromatic residue-rich amino-terminal segments of temporin L self-assemble into collagen-mimetic peptides with cell-adhesion properties.

The Journal of biological chemistry·2026
Same journal

YhbO is a DJ-1 family glyoxalase and α-oxoaldehyde hydratase that confers resistance to reactive carbonyl stress (112).

The Journal of biological chemistry·2026
Same journal

ARMH3 acts as a central scaffold at the Golgi/TGN through interactions with Arl5, GBF1, and PI4KB.

The Journal of biological chemistry·2026
See all related articles

RUNX1 transcription factor homodimerizes via its C terminus, a novel mechanism impacting hematopoietic stem cell differentiation. This dimerization is crucial for regulating gene expression and is frequently disrupted in human leukemia.

Area of Science:

  • Molecular Biology
  • Hematopoiesis
  • Cancer Biology

Background:

  • RUNX1 (AML1, CBFalpha2, PEBP2alphaB) is a critical transcription factor for hematopoietic stem cell establishment.
  • Previously, RUNX1 was understood to function as a monomer, interacting with DNA and co-factors via its N terminus.
  • Alterations in RUNX1, including gene fusions and point mutations, are common in human leukemia, but the underlying mechanisms remain unclear.

Purpose of the Study:

  • To investigate the dimerization potential of RUNX1 and its functional implications.
  • To elucidate the mechanism by which RUNX1 alterations contribute to hematopoietic transformation and leukemia.

Main Methods:

  • Reporter gene assays to assess RUNX1 activity.
  • Analysis of RUNX1's role in hematopoietic cell line differentiation.

Related Experiment Videos

  • Examination of RUNX1 binding site arrangements in target gene promoters.

    • Main Results:

    • RUNX1 was found to homodimerize through a C terminus-mediated interaction.
    • This RUNX1-RUNX1 interaction modulates the transcription factor's activity and its ability to induce hematopoietic differentiation.
    • The presence of multiple RUNX1 binding sites in gene promoters suggests a role for homodimerization in chromatin organization.

    Conclusions:

    • RUNX1 homodimerization is a key regulatory mechanism influencing hematopoietic differentiation.
    • Disruption of the RUNX1 dimerization region, through gene fusions or mutations observed in leukemia, likely impairs its differentiation-regulating functions.
    • This finding provides new insights into the pathogenesis of RUNX1-associated leukemias.